TRAIL and Hsp90 inhibition 19. Palacios C, Lopez‐Perez AI, Lopez‐Rivas A. Down‐regulation of RIP expression by 17‐ dimethylaminoethylamino‐17‐demethoxygeldanamycin promotes TRAIL‐induced apoptosis in breast tumor cells. Cancer Lett 2010; 287(2):207‐215. 20. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor‐related apoptosis‐inducing ligand. J Biol Chem 2005; 280(49):40599‐40608. 21. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J et al. Kinome profiling of non‐canonical TRAIL signaling reveals RIP1‐Src‐STAT3 dependent invasion in resistant non‐small cell lung cancer cells. J Cell Sci 2012. 22. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A 2003; 100(24):13791‐13796. 23. Siegelin MD, Habel A, Gaiser T. 17‐AAG sensitized malignant glioma cells to <strong>death</strong>‐<strong>receptor</strong> mediated apoptosis. Neurobiol Dis 2009; 33(2):243‐249. 24. Vasilevskaya IA, O'Dwyer PJ. 17‐Allylamino‐17‐demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem <strong>Pharma</strong>col 2005; 70(4):580‐589. 25. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004; 3(12):1530‐1536. 26. de CG. Heat shock protein 90 regulates the metaphase‐anaphase transition in a polo‐like kinase‐dependent manner. Cancer Res 2004; 64(15):5106‐5112. 27. Georgakis GV, Li Y, Rassidakis GZ, Martinez‐Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17‐allylamino‐17‐demethoxy‐geldanamycin in Hodgkin's lymphoma cells down‐regulates Akt kinase, dephosphorylates extracellular signal‐ regulated kinase, and induces cell cycle arrest and cell <strong>death</strong>. Clin Cancer Res 2006; 12(2):584‐590. 28. Arya R, Mallik M, Lakhotia SC. Heat shock genes ‐ integrating cell survival and <strong>death</strong>. J Biosci 2007; 32(3):595‐610. 29. Eid MA, Lewis RW, Abdel‐Mageed AB, Kumar MV. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB‐mediated inhibition of caspases and Bid activation. Int J Oncol 2002; 21(1):111‐117. 30. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91(12):4624‐4631. 31. Zhang L, Fang B. Mechanisms of resistance to TRAIL‐induced apoptosis in cancer. Cancer Gene Ther 2005; 12(3):228‐237. 32. Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR et al. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Mol Cancer Ther 2007; 6(7):2029‐2038. 33. Belyanskaya LL, Ziogas A, Hopkins‐Donaldson S, Kurtz S, Simon HU, Stahel R et al. TRAIL‐ induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL‐R2/DR5 expression in the absence of caspase‐8. Lung Cancer 2008; 60(3):355‐365. 34. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107(17):2250‐2256. 35. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012; 1823(3):742‐755. ‐ 97 ‐
Chapter 5 ‐ 98 ‐